Clinical Trial Update: Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial comparing 23 mg sustained-release donepezil to 10 mg immediate-release donepezil in moderate-to-severe Alzheimer's disease; results have been post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Aricept 10 mg IR (donepezil hydrochloride)
• Aricept 23 mg SR (donepezil hydrochloride)

Snippet

Sponsor: Eisai Inc. | Conditions: Alzheimer's Disease | Phase 3 | Status: COMPLETED | Results posted: 2013-02-05